OTCMKTS:FLWPF

The Flowr Competitors

$0.22
-0.01 (-2.41 %)
(As of 04/20/2021 05:19 PM ET)
Add
Compare
Today's Range
$0.22
Now: $0.22
$0.23
50-Day Range
$0.25
MA: $0.26
$0.29
52-Week Range
$0.22
Now: $0.22
$0.55
Volume123,693 shs
Average Volume218,857 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

The Flowr (OTCMKTS:FLWPF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying FLWPF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to The Flowr, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Abacus Health Products (OTCMKTS:ABAHF) and The Flowr (OTCMKTS:FLWPF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Earnings and Valuation

This table compares Abacus Health Products and The Flowr's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abacus Health ProductsN/AN/AN/AN/AN/A
The FlowrN/AN/AN/AN/AN/A

Profitability

This table compares Abacus Health Products and The Flowr's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abacus Health ProductsN/AN/AN/A
The FlowrN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Abacus Health Products and The Flowr, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abacus Health Products0000N/A
The Flowr00203.00

The Flowr has a consensus price target of $2.20, indicating a potential upside of 889.65%. Given The Flowr's higher probable upside, analysts plainly believe The Flowr is more favorable than Abacus Health Products.

Summary

The Flowr beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

The Flowr (OTCMKTS:FLWPF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Earnings & Valuation

This table compares The Flowr and Acreage's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrN/AN/AN/AN/AN/A
AcreageN/AN/AN/AN/AN/A

Profitability

This table compares The Flowr and Acreage's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
AcreageN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for The Flowr and Acreage, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr00203.00
Acreage01202.67

The Flowr currently has a consensus target price of $2.20, indicating a potential upside of 889.65%. Acreage has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given The Flowr's stronger consensus rating and higher probable upside, equities research analysts plainly believe The Flowr is more favorable than Acreage.

Summary

The Flowr beats Acreage on 2 of the 2 factors compared between the two stocks.

The Flowr (OTCMKTS:FLWPF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for The Flowr and Applied Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr00203.00
Applied Biosciences0000N/A

The Flowr currently has a consensus target price of $2.20, indicating a potential upside of 889.65%. Given The Flowr's higher possible upside, research analysts plainly believe The Flowr is more favorable than Applied Biosciences.

Profitability

This table compares The Flowr and Applied Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
Applied BiosciencesN/AN/AN/A

Earnings & Valuation

This table compares The Flowr and Applied Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrN/AN/AN/AN/AN/A
Applied BiosciencesN/AN/AN/AN/AN/A

Summary

The Flowr beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and The Flowr (OTCMKTS:FLWPF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Profitability

This table compares Ayr Strategies and The Flowr's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
The FlowrN/AN/AN/A

Earnings and Valuation

This table compares Ayr Strategies and The Flowr's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
The FlowrN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Ayr Strategies and The Flowr, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
The Flowr00203.00

Ayr Strategies presently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. The Flowr has a consensus price target of $2.20, suggesting a potential upside of 889.65%. Given The Flowr's stronger consensus rating and higher possible upside, analysts plainly believe The Flowr is more favorable than Ayr Strategies.

Summary

The Flowr beats Ayr Strategies on 2 of the 3 factors compared between the two stocks.

Can B (NASDAQ:CANB) and The Flowr (OTCMKTS:FLWPF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Can B and The Flowr's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
The FlowrN/AN/AN/AN/AN/A

Profitability

This table compares Can B and The Flowr's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
The FlowrN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Can B and The Flowr, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
The Flowr00203.00

The Flowr has a consensus target price of $2.20, suggesting a potential upside of 889.65%. Given The Flowr's higher probable upside, analysts plainly believe The Flowr is more favorable than Can B.

Summary

The Flowr beats Can B on 2 of the 2 factors compared between the two stocks.

The Flowr (OTCMKTS:FLWPF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Valuation & Earnings

This table compares The Flowr and Cansortium's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Profitability

This table compares The Flowr and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
CansortiumN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for The Flowr and Cansortium, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr00203.00
Cansortium00103.00

The Flowr presently has a consensus price target of $2.20, suggesting a potential upside of 889.65%. Cansortium has a consensus price target of $1.20, suggesting a potential upside of 11.11%. Given The Flowr's higher probable upside, equities analysts plainly believe The Flowr is more favorable than Cansortium.

Summary

The Flowr beats Cansortium on 2 of the 2 factors compared between the two stocks.


The Flowr Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84-5.4%$0.00N/A0.00News Coverage
Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77-0.0%$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.21-81.0%$0.00N/A0.00Increase in Short Interest
Gap Down
AYRSF
Ayr Strategies
1.4$21.26-0.0%$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.52-3.5%$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
0.9$1.13-4.5%$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$3.90-2.8%$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.09-2.3%$0.00N/A0.00Gap Up
CPHRF
Cipher Pharmaceuticals
1.2$1.07-0.9%$0.00N/A0.00
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.20-15.0%$0.00N/A0.00News Coverage
Gap Up
Cosmos logo
COSM
Cosmos
0.5$6.30-8.7%$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.3$11.25-6.5%$0.00N/A0.00
Curaleaf logo
CURLF
Curaleaf
1.6$12.77-2.5%$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00-33.3%$0.00N/A0.00Gap Up
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.15-1.7%$0.00N/A0.00
EVIO logo
EVIO
EVIO
0.6$0.00-8.7%$0.00N/A0.00
Flower One logo
FLOOF
Flower One
0.4$0.19-13.5%$0.00N/A0.00High Trading Volume
Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05-0.0%$0.00N/A0.00Gap Down
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01-11.3%$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$26.82-1.2%$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.57-6.3%$0.00N/A0.00
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.85-0.7%$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01-11.8%$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$65.83-5.2%$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.18-6.7%$0.00N/A0.00Gap Up
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.27-2.4%$0.00N/A0.00Gap Up
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04-0.0%$0.00N/A0.00Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.06-0.2%$0.00N/A0.00
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.38-10.2%$0.00N/A0.00Gap Down
KHTRF
Knight Therapeutics
1.2$4.15-0.7%$0.00N/A0.00
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01-1.4%$0.00N/A0.00
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.05-1.0%$0.00N/A0.00News Coverage
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.37-1.4%$0.00N/A0.00Increase in Short Interest
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.26-7.7%$0.00N/A0.00Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.05-1.3%$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.06-16.8%$0.00N/A0.00Gap Up
MYHI
Mountain High Acquisitions
0.5$0.02-17.0%$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.34-6.7%$0.00N/A0.00Gap Up
Plus Products logo
PLPRF
Plus Products
1.1$0.51-2.0%$0.00N/A0.00Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00-4.0%$0.00N/A0.00
PCYN
Procyon
0.4$0.60-0.0%$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01-2.8%$0.00N/A0.00Gap Up
SANP
Santo Mining
0.5$0.00-16.3%$0.00N/A0.00Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$12.76-2.1%$0.00N/A0.00Increase in Short Interest
News Coverage
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40-0.0%$0.00N/A0.00News Coverage
TerrAscend logo
TRSSF
TerrAscend
1.7$9.95-1.9%$0.00N/A0.00
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.2$0.28-8.1%$0.00N/A0.00Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.